These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Abbott agrees to expanded access for ritonavir.
    Author: Baker R.
    Journal: BETA; 1995 Sep; ():4. PubMed ID: 11362891.
    Abstract:
    At a meeting with community treatment advocates in Chicago, Abbott Laboratories agreed to expand its access program for ritonavir (ABT-538). A complete patient eligibility profile for enrollment in the open label protocol for the drug has not yet been formulated. It appears that in vitro, ritonavir increases the concentration of saquinavir by 100-fold. Earlier reports of elevated liver enzymes from ritonavir are unfounded. Discussions between Roche and Abbott are underway for a clinical study of the double combination of ritonavir and saquinavir. Roche and Merck are also planning a double combination clinical study of Invirase plus Crixivan.
    [Abstract] [Full Text] [Related] [New Search]